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PPeripheral and Pulmonary Artery Disease
he Novel Phosphodiesterase
nhibitor NM-702 Improves
laudication-Limited Exercise Performance
n Patients With Peripheral Arterial Disease
ric P. Brass, MD, PHD,* Richard Anthony, PHD,† Frederick R. Cobb, MD,‡ Isao Koda, PHD,§
enny Jiao, PHD,† William R. Hiatt, MD
orrance and Pasadena, California; Durham, North Carolina; and Denver, Colorado
OBJECTIVES The current study tested the hypothesis that NM-702 improves treadmill exercise perfor-
mance in peripheral arterial disease patients with claudication-limited exercise performance.
BACKGROUND Patients with claudication experience significant disability, owing to their exercise limitation.
Therapeutic options to improve exercise performance in these patients are limited. NM-702
is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
METHODS This study was a randomized, multi-center, placebo-controlled, double-blind trial. Patients
were randomized to receive 24 weeks of twice-daily treatment with either placebo (intent to
treat population, n  130), 4 mg NM-702 (n  126), or 8 mg NM-702 (n  130).
RESULTS After 24 weeks of treatment, 8 mg NM-702 was associated with a statistically significant
increased peak walking time on a graded treadmill as compared with placebo (p  0.004).
Peak walking time after 24 weeks was increased by 17.1  49.0% in the placebo arm, 22.1 
60.1% in the 4-mg NM-702 arm, and 28.1  50.5% in the 8-mg NM-702 arm. NM-702 at
the 8-mg dose for 24 weeks was associated with statistically significant improvements in the
treadmill claudication onset time as compared with placebo. In addition, as compared with
placebo, NM-702 improved the physical component and physical functioning scores of the
Medical Outcomes Study 36-Item Short Form and the walking distance and stair climbing
domains of the Walking Impairment Questionnaire. NM-702 was generally well tolerated,
but adverse events typical of vasodilators were common.
CONCLUSIONS NM-702 used for 24 weeks by patients with claudication was associated with improvements
in laboratory- and ambulatory-based exercise performance. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.0642539–45) © 2006 by the American College of Cardiology Foundation
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sower extremity peripheral arterial disease (PAD) is a
revalent manifestation of systemic atherosclerosis. Patients
ith PAD are at high risk for cardiovascular morbidity and
ortality, and strategies to reduce systemic cardiovascular
isk are the cornerstone of PAD therapy (1). However,
AD is also associated with substantial functional disability
ue to impaired walking performance (1,2). Exercise reha-
ilitation, drug therapy, and selective use of revasculariza-
ion are options for improving exercise performance in
laudicants (1,3). The efficacy of cilostazol, a selective
nhibitor of phosphodiesterase type III, in improving walk-
ng capacity in PAD patients (4) has led to interest in other
hosphodiesterase inhibitors as treatments for claudication.
From the *Department of Medicine, Harbor-UCLA Medical Center, Torrance,
alifornia; †Catalyst Pharmaceutical Research, Inc., Pasadena, California; §Nissan
hemical America, Pasadena, California; ‡Durham VA Medical Center, Durham,
orth Carolina; and the University of Colorado, Divisions of Geriatrics and
ardiology, and the Colorado Prevention Center, Denver, Colorado. This study was
upported and sponsored by Nissan Chemical Industries, Ltd., Tokyo, Japan. Drs.
rass, Hiatt, and Cobb were paid consultants to the trial’s sponsor. Drs. Anthony and
iao are employed by the contract research organization that conducted the study on
he sponsor’s behalf. Dr. Koda is employed by the trial’s sponsor. Dr. Cobb died
nexpectedly during the preparation of this work.i
Manuscript received April 12, 2006; revised manuscript received June 26, 2006,
ccepted July 23, 2006.NM-702 (4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-
3-pyridylmethylamino]-3[2H]-pyridazinone hydrochlo-
ide) is an inhibitor of phosphodiesterase (5). NM-702
hows selectivity for phosphodiesterase isoforms III and V
n the basis of study of phosphodiesterases extracted from
abbit heart and platelets. NM-702 also inhibits human
latelet thromboxane A2 synthase at concentrations that
nhibit rabbit phosphodiesterase (5). This profile suggests
hat NM-702 might have efficacy in the treatment of
laudication-limited exercise impairment. Phase I and II
tudies have demonstrated that the drug is well tolerated
nd might improve treadmill performance in claudicants.
he current study was designed to evaluate the potential
fficacy of NM-702 at doses of 4 mg or 8 mg twice daily and
ssess its safety in patients with PAD.
ETHODS
verview of study design. The study was a 3-armed,
andomized, double-blinded, placebo-controlled, multi-
enter trial conducted at 18 sites in the U.S. (Appendix).
fter screening evaluations and baseline qualification mea-
urements (see the following text), patients were random-
zed to twice-daily doses of placebo, 4 mg NM-702, or 8 mg
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NM-702 Improves Exercise Performance in PAD December 19, 2006:2539–45M-702. Patients remained on study medication for 24
eeks. The protocol was reviewed and approved by appro-
riate institutional review committees, and all patients
rovided written informed consent.
A steering committee (E.P.B., R.A., F.R.C., I.K., and
.R.H.) was responsible for design of the study, oversight
f its implementation, and analysis of the data. The Com-
ittee’s Charter defined its role and independence as well as
he sponsor’s commitment to publish the study results in a
imely manner.
atient selection. Patients were recruited from clinics at
he study sites and through community-based advertising.
er protocol, all participants were a minimum of 50 years
ld and had a history of clinically stable claudication for a
eriod of at least 3 months. A diagnosis of PAD was
onfirmed in each patient on the basis of a resting ankle-
rachial index (ABI) of0.90 in the symptomatic leg or for
iabetic patients with noncompressible vessels (ABI
1.30), a toe-brachial index (TBI) of 0.70. The ABI was
alculated with the higher of the 2 systolic blood pressures
easured in the upper extremity and the higher of the
easured dorsalis pedis or posterior tibial pressures mea-
ured in each leg (6). The TBI was measured with standard
ethodologies (7).
Patients were excluded from study participation if they
ad ischemic rest pain or ulceration, exercise performance
imited by any condition other than claudication, had
ndergone a revascularization procedure within 12 weeks,
uffered a myocardial infarction or stroke within 6 months
f potential study drug initiation, had a resting upper
xtremity blood pressure exceeding 150/100 mm Hg, or
ere pregnant or lactating. Clinically significant laboratory
bnormalities on screening were also exclusionary, including
prothrombin time 2 times the upper limit of normal; a
latelet count of 50,000/mm3; a hematocrit 60% or
30%; a hemoglobin A1c 12%; low-density lipoprotein
holesterol 160 mg/dl; a serum creatinine 3.0 mg/dl; or
ilirubin, alanine aminotransferase, or aspartate amino-
ransferase more than 3 times the upper limit of normal.
Patients must have been off claudication pharmacother-
py (including cilostazol or pentoxyfylline) or treatment
Abbreviations and Acronyms
ABI  ankle-brachial index
ANCOVA  analysis of covariance
COT  claudication onset time
NM-702  4-bromo-6-[3-(4-chlorophenyl)propoxy]-
5-(3-pyridylmethylamino)-3(2H)-
pyridazinone hydrochloride
PAD  peripheral arterial disease
PWT  peak walking time
SF-36  Medical Outcomes Study 36-Item
Short Form
TBI  toe-brachial index
WIQ  Walking Impairment Questionnaireith other phosphodiesterase inhibitors (for example, silde- wafil) for a period of at least 4 weeks before any baseline
ssessments, and use of these drugs was not permitted until
ompletion of the week-24 efficacy assessments and conclu-
ion of study drug treatment. Patients were permitted to use
spirin or clopidogrel. However, owing to the antiplatelet
ffects of NM-702, for potential safety reasons participants
ere not permitted to use combination aspirin plus clopi-
ogrel therapy during the study.
aseline assessments. At an initial screening visit, patients
nderwent a full medical history and physical examination,
emodynamic assessments, electrocardiogram, and familiar-
zation with the treadmill procedures. Participants returned
or 3 baseline visits, at each of which a treadmill test to
easure peak walking time (PWT) and claudication onset
ime (COT) was performed. These visits were separated by
etween 3 and 10 days. At the first of these baseline visits,
lood was also obtained for baseline and exclusionary
aboratory assessments.
For analysis purposes, a patient’s baseline exercise perfor-
ance was defined as the median value from the 3 baseline
ests for PWT and COT. Patients with a median baseline
WT of 90 s and 600 s qualified for randomization.
reatment phase. After completion of 3 baseline treadmill
ests, patients meeting inclusion/exclusion criteria were
andomized to 1 of the 3 treatment arms. At the time of
andomization patients also completed the Medical Out-
omes Study 36-Item Short Form (SF-36) health-related
uality-of-life instrument and the Walking Impairment
uestionnaire (WIQ) (8). Patients returned to the study
ite for visits 6, 12, 18, and 24 weeks after randomization.
t each visit study medication was dispensed (except at the
4-week visit), and adverse events and concomitant medi-
ations reviewed. At the week 12 and 24 visits, hemody-
amic status was assessed, treadmill testing performed, and
he SF-36 and WIQ were administered. Active treatment
ith study medication was discontinued after the 24-week
isit, and a final visit for safety purposes occurred 12 months
fter randomization. Only information on serious adverse
vents and mortality were collected between the week 24
nd month 12 visits.
readmill testing. Claudication-limited exercise perfor-
ance was quantified with a graded treadmill exercise test.
t time 0, the patients stepped onto the treadmill, which
as moving at 2 mph at a 0% grade. At 2-min intervals the
rade was increased by 2% as per Gardner et al. (9). The
atient continued on the treadmill until they could not walk
ny further, and the time at which this occurred was
esignated as the PWT. The COT, defined as the time on
he treadmill at which claudication symptoms were first
eported, was also recorded for each test. All treadmill
esting was performed at least 2 h after the last study drug
ose. A quality control program was provided to the sites to
nsure that the treadmill testing procedures were performed
onsistently and according to protocol.
tatistical analysis. The primary end point for this trial
as the change in PWT between baseline and 24 weeks.
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December 19, 2006:2539–45 NM-702 Improves Exercise Performance in PADhanges from baseline in treadmill data were analyzed on
he basis of log-transformed data [i.e., ln(PWT at 24 weeks)
n(PWT at baseline), which is the same as the ln ratio]. The
se of natural log-transformed data was prospectively de-
ned, owing to the anticipated skewed distribution of the
alking time data. Comparisons between treatment arms
ere done with analysis of covariance (ANCOVA), which
ncluded treatment, smoking status, baseline ln(PWT), and
nvestigator site as main effects. Treatment effects on COT
ere analyzed in a similar manner. Similarly, SF-36 and
IQ data were also analyzed with ANCOVA with adjust-
ent for demographic variables, baseline scores, and smok-
ng and diabetic status. Last observation carried forward was
sed to replace any missing data.
Changes in limb hemodynamic status between baseline
nd 12 or 24 weeks were categorized as increased by 15% or
ore, decreased by 15% or more, or as unchanged (within
5% of baseline). Effects of treatment were assessed with a
hi-square test.
The study was designed to allow for independent assess-
ent for the effects of either the 4-mg or the 8-mg dose as
ompared with placebo, and thus for sample size consider-
tions, each dosed group was independently powered at an
lpha  0.025 level. A sample size of 117 patients/arm
ould provide 90% power, assuming a 25% increase in
WT in the placebo group, a 65% increase in the treatment
roup(s), and an 85% coefficient of variation for the absolute
WTs. A sample size of 130 patients/arm was elected to
llow for patients who withdrew from the study early.
Statistical inference for the primary efficacy variable
PWT change at 24 weeks) was made on the basis of
ochberg multiple testing procedure for the efficacy of
ach dose. The requirement for claiming that both doses
ere efficacious was a p value 0.05 for both the 4-mg
M-702 versus placebo and 8-mg NM-702 versus pla-
ebo comparisons. If 1 comparison failed to meet the p 
.05 criterion, the pair-wise comparison for each dose
Table 1. Demographics and Baseline Characte
Age in yrs, mean (range)
Gender, male/female
Race (%)
White
Black
Hispanic
Other
Diabetic (%)
ABI (mean  SD)
Cigarette smoking (%)
Never smoked
Previous, quit within past 5 yrs
Previous, quit 5 yrs ago
Current smoker
Baseline peak walking time, s (mean  SD)
Baseline claudication-onset time, s (mean  SD)ABI  ankle-brachial index in the symptomatic limb.ersus placebo was examined with the more stringent
riterion of p  0.025 required for inferring efficacy at
hat dose. No adjustments for significance levels were
ade for other statistical tests performed, and a p  0.05
as used for statistical inferences.
ESULTS
emographics and baseline characteristics. A total of
91 patients were randomized. Of this total, 5 were ex-
luded from the intent-to-treat analysis because they never
eceived a dose of study medication. Patients seemed to
eflect the general claudication population, because they
veraged approximately 67 years of age, they were predom-
nately male, most were either current or past smokers, and
pproximately 42% were diabetic patients (Table 1). Partic-
pants’ ABIs averaged 0.64 on entry, and their baseline
erformance on the treadmill was consistent with moderate
o severe performance limitation due to claudication
Table 1). Six patients, 2 in the 4-mg NM-702 arm and 4
n the 8-mg NM-702 arm, entered the study on the basis of
BI measurements. Patients randomized to the 3 study
rms were similar, except that there was a significant
ifference in the distribution of race amongst the arms (p 
.003) (Table 1).
readmill end points. A total of 11.5% of patients receiv-
ng placebo, 17.5% of patients in the 4-mg NM-702 arm,
nd 22.3% of patients in the 8-mg dosing arm withdrew
rom the study before completing 24 weeks of treatment and
he 24-week treadmill assessment. Of the 15 patients in the
lacebo group who withdrew, 7 made a decision to with-
raw without providing additional information, 5 withdrew
wing to an adverse experience, and 1 each were withdrawn
wing to a sponsor decision, a physician decision, and after
oting failure to meet entry criteria. Similarly, of the
ithdrawal of 22 patients in the 4-mg NM-702 group, 11
ere on the basis of patient decision, 4 owing to an adverse
s of the Intention-to-Treat Population
lacebo
 130)
4 mg NM-702
(n  126)
8 mg NM-702
(n  130)
1 (50–85) 66.5 (50–89) 67.0 (50–89)
106/24 106/20 109/21
94.6 90.5 77.7
4.6 7.1 16.9
0.8 1.6 2.3
0 0.8 3.1
39.2 45.2 41.5
5  0.16 0.63  0.16 0.64  0.14
6.9 7.1 5.4
18.5 15.9 20.0
39.2 42.9 43.8
35.4 34.1 30.8
6  126.7 282.9  122.3 306.6  135.2
4  63.0 122.3  63.9 125.7  63.6ristic
P
(n
68.
0.6
271.
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NM-702 Improves Exercise Performance in PAD December 19, 2006:2539–45vent, 4 were lost to follow-up, 2 were on the basis of
hysician decision, and 1 was because of death. In the 8-mg
M-702 group, 15 patient withdrawals were on the basis of
atient decision, 8 were owing to an adverse event, and 6
atients were lost to follow-up.
On the basis of the protocol’s primary end point analysis,
he model-adjusted PWT ratio (least-square mean) for
WT at 24 weeks versus baseline was 1.07 for placebo, 1.12
or 4 mg NM-702, and 1.21 for 8 mg NM-702. The
air-wise comparisons for each dosed arm yielded p 0.259
or 4 mg NM-702 versus placebo and p  0.004 for 8 mg
M-702 versus placebo. Thus, the 8-mg NM-702 dose was
ssociated with a statistically significant increase in PWT.
he PWT ratio of 1.21 for the 8-mg NM-702 group
orresponded to an absolute increase in PWT of 68 s
ompared with 35 s receiving placebo (Table 2). Expressed
s a percent change from baseline, the 8-mg twice daily.
M-702 dose was associated with a 28.1% increase in
WT, as compared with 17.1% receiving placebo. The
ncrease in PWT seemed to be both time and dose depen-
ent (Fig. 1). Importantly, 68% of subjects reported taking
heir last dose of study medication at least 9 h before the
ime of the 24-week treadmill test. A linear dose-response
elationship was present across the treatment arms (p 
.004).
Limiting analysis to a per-protocol population that re-
eived at least 80% of study drug doses, did not use
entoxyfylline or cilostazol during the treatment period, and
ompleted a week-24 treadmill increased the numeric effect
f NM-702 but did not change the statistical conclusions
least-square mean ratio week-24 vs. baseline 1.07 on
lacebo, 1.19 on 4 mg NM-702, pair-wise p  0.065 vs.
lacebo, and 1.27 on 8 mg NM-702, pair-wise p  0.003
s. placebo). Approximately 72% of the intent-to-treat
ohort qualified for this per-protocol analysis.
The conclusion that 24 weeks of NM-702 treatment
mproved PWT was supported by analysis of subpopula-
able 2. Treadmill Performance in the Intention-to-Treat
opulation
Change in Peak Walking Time
(s, Mean  SD)
Placebo
4 mg
NM-702
8 mg
NM-702
2 weeks 25.4  95.4 39.9  100.3 43.3  107.9
4 weeks 34.5  116.3 52.0  134.4 67.6  125.1
Change in Claudication Onset Time
(s, Mean  SD)
Placebo
4 mg
NM-702
8 mg
NM-702
2 weeks 22.4  58.0 30.9  66.3 34.2  72.7
4 weeks 28.1  72.2 45.8  108.4 49.3  91.6
issing data were replaced with last observation carried forward. Data are from 130
atients in the placebo arm, 126 patients in the 4-mg arm, and 130 patients in the
-mg arm. Peak walking time and claudication onset time were significantly increased
y the 8-mg dose as compared with placebo (on the basis of analysis of covariance
erformed on ln-ratios—see text).
w
mions stratified by diabetic status, race, or body mass index
data not shown). Smoking status did seem to affect the
WT response (p  0.007), with current smokers having
arger percent increases in PWT in each group, but NM-
02 was numerically superior to placebo in each smoking
tatus cohort (data not shown).
emodynamic status. Hemodynamic status as assessed by
BI was stable in the majority of patients over the 24 weeks
f treatment and was unaffected by NM-702. At week-24,
he mean ABI was 0.67 in all treatment arms and did not
iffer in any group from baseline assessments. With the
rotocol definition of a 15% change in hemodynamic status
s potentially clinically significant, the number of patients
howing increases in ABI or TBI was not different between
reatment arms (Table 3).
uestionnaire-based assessments. All treatment arms
ere considered comparable at baseline with respect to
F-36 and WIQ assessments of ambulatory functional
tatus (Table 4). NM-702 treatment for 24 weeks was
ssociated with statistically significant improvements in the
F-36 physical component score, SF-36 assessed physical
unctioning, WIQ walking distance summary, and the
IQ stair climbing summary (Table 4). In contrast, the
F-36 mental component summary and the WIQ walking
peed summary were not affected by treatment.
igure 1. The percent change in peak walking time as a function of time.
ata are mean values  SEM for the intention to treat population with
issing data replaced by last observation carried forward. Solid circles 
lacebo group; open squares  4-mg NM-702 group; open triangles 
-mg NM-702 group.
able 3. Change in ABI or TBI Measurements After 24 Weeks
Placebo
(n  130)
4 mg NM-702
(n  126)
8 mg NM-702
(n  130)
ncreased 22.3% 29.4% 28.5%
o change 66.9% 59.5% 64.6%
ecreased 10.8% 11.1% 6.9%
nkle brachial indexes (ABIs) or toe brachial indexes (TBIs) (in diabetics with
oncompressible vessels) were measured at baseline and at 24 weeks in the intention-
o-treat population, with missing data replaced by last observation carried forward.
ndividual patients were characterized as having an increase in their ABI or TBI if the
4-week value was 15% higher than baseline or having a decrease if the 24-week
alue was 85% of the baseline value. Patients not meeting either of these criteria
ere characterized as having no change. The percentage of each treatment arm
eeting each criterion is shown in the table.
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December 19, 2006:2539–45 NM-702 Improves Exercise Performance in PADafety. During the treatment phase of the study (6 months
f planned study drug exposure plus 1 month additional
bservation) there were a total of 3 deaths (1 in the placebo
rm and 2 in the 4-mg NM-702 arm). Two of the 3 deaths
1 in the placebo arm and 1 in the 4-mg NM-702 group)
ccurred within 6 months of randomization but after study
rug was discontinued for other reasons. During the addi-
ional 5 months of observation (completing 1 year total
bservation, the last 6 months of which were off drug) there
ere 5 more deaths (3 in the placebo arm, 1 in the 4-mg
M-702 arm, and 1 in the 8-mg NM-702 arm).
One or more adverse events were experienced by 70%,
7%, and 79% of the subjects in the placebo, 4-mg NM-
02, and 8-mg NM-702 treatment arms, respectively. Of
hese, 86% of the total adverse events were assessed as mild
r moderate in intensity by the site investigators. Symptoms
nticipated on the basis of NM-702’s mechanism of action
ere seen at increased frequency in patients receiving
M-702 but were usually mild to moderate in severity and
ypically were not associated with discontinuation of study
edication (Table 5). Symptoms and signs potentially
elated to tachyarrhythmias were also more common in
atients receiving NM-702, and in most cases these were
inus tachycardias. Several cases of atrial flutter or fibrilla-
able 4. Effect of NM-702 on Questionnaire-Based Patient Asse
Placebo
n Baseline
Change
24 Week
F-36 physical component summary 127 36.0  8.3 0.1  6
F-36 mental component summary 127 54.7  10.5 1.6  8
F-36 physical functioning 127 44.3  18.9 0.5  1
IQ, walking distance summary 129 22.4  22.9 1.6  1
IQ, walking speed summary 129 26.6  21.6 3.9  1
IQ, stair climbing summary 129 33.9  24.9 1.9  2
alues are mean  SD. Note that n represents those patients for whom baseline data
SF-36) physical component score (p 0.031), SF-36 physical functioning score (p
nd WIQ stair climbing (p  0.012) were statistically significant.
able 5. Selected Adverse Events Observed at Increased
requency With NM-702
Placebo
(n  130)
4 mg
NM-702
(n  126)
8 mg
NM-702
(n  130)
echanism-based symptoms
Palpitations 0 9 13
Diarrhea 4 13 19
Nausea 1 3 6
Dizziness/lightheadedness 4 9 13
Headache 2 6 9
achyarrhythmias
Tachycardia 1 3 10
Atrial fibrillation 1 1 1
Atrial flutter 0 0 2
Arrhythmia (not specified) 0 0 1
Syncope 0 1 4
leeding or coagulopathy 4 1 6dverse events were collected throughout the 6 months of planned treatment and for
n additional 30 days. The numbers of patients experiencing each event are tabulated.
a
eion were observed in patients taking NM-702, and 4
atients receiving 8 mg twice daily. NM-702 experienced
yncope without documentation of the associated cardiac
hythm (Table 5), 2 of which were characterized as serious
dverse events (Table 6). Four cases of gout or gout
xacerbation were observed in the 8-mg NM-702 arm, with
o cases in either of the 2 other arms. No other trends
uggesting unanticipated adverse events associated with
M-702 were noted.
Serious adverse events were experienced by 33, 28, and 29
ubjects in the placebo, 4-mg NM-702, and 8-mg NM-702
reatment arms, respectively. Given the high prevalence of
ardiovascular complications in the PAD population and
he mechanism of action of NM-702, particular attention
as paid to cardiac serious adverse events (Table 6). There
ere no trends suggesting that NM-702 was associated with
ncreased frequencies of serious cardiac ischemic events or
ongestive heart failure.
Because NM-702 affects platelet function, bleeding ad-
erse events were reviewed in detail. Sixty-nine percent of
he subjects were taking aspirin during the study, and 16%
ere taking clopidogrel, and there were no significant
ifferences between treatment groups in the use of these
rugs. A total of 5 subjects used coumadin during the study
reatment period (1 receiving placebo and 4 receiving 8 mg
M-702). Eleven patients (4 receiving placebo, 1 receiving
mg NM-702, and 6 receiving 8 mg NM-702) experienced
nts in the Intention-to-Treat Population
4 mg Twice Daily NM-702 8 mg Twice Daily NM-702
n Baseline
Change at
24 Weeks n Baseline
Change at
24 Weeks
123 34.4  7.5 2.3  6.9 128 35.7  8.3 1.9  7.0
123 53.9  10.5 1.0  8.4 128 53.9  10.5 0.1  8.6
126 41.4  17.0 4.5  14.4 130 44.8  18.3 3.8  17.4
125 20.4  19.6 8.3  24.0 129 20.2  19.8 8.4  20.2
125 28.4  22.8 1.0  20.3 129 26.9  24.5 4.8  21.3
125 33.7  24.0 6.6  24.2 129 37.9  23.8 9.2  23.9
vailable. The treatment effect on the Medical Outcomes Study 36-Item Short Form
, Walking Impairment Questionnaire (WIQ) walking distance summary (p 0.026),
able 6. Cardiac Serious Adverse Events
Placebo
(n  130)
4 mg
NM-702
(n  126)
8 mg
NM-702
(n  130)
schemic syndromes (angina,
unstable angina, myocardial
infarction, chest pain)
4 4 4
ongestive heart failure 2 1 0
trial flutter 0 0 1
ulmonary edema 1 0 0
yncope 0 0 2
mplantable defibrillator
replacement
0 0 2
ardiac serious adverse events observed during the 6-month study, plus those from anssme
at
s
.6
.2
5.8
6.6
7.4
2.6
were additional 1-month observation period are presented. The numbers of patients
xperiencing each event are shown.
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wo of the bleeding adverse events, both in patients taking
mg NM-702, were serious. One serious adverse event
nvolved a patient using warfarin who was admitted to the
ospital without bleeding but had an international normal-
zed ratio of 11.8. The second serious event involved a
atient taking warfarin and aspirin who was hospitalized
ith a gastrointestinal bleed.
ISCUSSION
M-702 use for 24 weeks was associated with statistically
ignificant improvements in treadmill and ambulatory-
ased performance in patients with claudication. The effi-
acy of NM-702 in improving treadmill PWT as assessed in
he primary efficacy analysis was supported by several
re-specified secondary analyses. Analysis of a per-protocol
opulation enriched for patients who adhered to the med-
cation dosing over 24 weeks demonstrated a numerically
arger improvement as compared with the intention to treat
opulation, as would be anticipated if drug exposure was
esponsible for the effect observed. There was a significant
elationship between NM-702 dose and the degree of PWT
mprovement. NM-702 was also superior to placebo when
linically relevant stratifications of the study population
ere analyzed. Claudication onset time showed a statisti-
ally significant response to NM-702 similar to that ob-
erved on analysis of PWT. Most 24-week treadmills were
btained at least 9 h after the last dose of study medication,
upporting efficacy of NM-702 throughout the dosing
nterval. Finally, the laboratory-based improvement in
readmill walking performance was confirmed with the
mbulatory-based questionnaires.
The magnitude of improvement seen with NM-702
reatment is likely to be clinically meaningful. The changes
n treadmill performance and questionnaire assessments
ssociated with 8 mg NM-702 are very similar to those
bserved with the use of cilostazol (10), which is approved
n the U.S. for the treatment of claudication. Clinical
elevance is also supported by the benefit of NM-702 on both
nstruments used to assess community-based performance in
he setting of the patients’ daily activities (Table 4).
Although NM-702 is known to be an inhibitor of
hosphodiesterase activities and of thromboxane A2 syn-
hase (5), how these effects relate to the improvement in
laudication-limited performance is unknown. Cilostazol
s also a phosphodiesterase inhibitor (4), suggesting that
his activity might be relevant. However, whether the
arget tissue is the vasculature, muscle, or platelet is
nclear. Of note, no changes in large vessel hemodynamic
tatus as assessed by ABI were observed with NM-702
se (Table 3). However, post-exercise ABIs were not
ssessed, and thus dynamic changes in hemodynamic
tatus can not be excluded.
NM-702 was generally well tolerated, with dropout rates
nly modestly higher in the 8-mg arm as compared with thelacebo arm. Nonetheless, mechanism-based adverse events
ere common with NM-702 dosing (Table 5). Concerns
ave been expressed about the cardiovascular risks associ-
ted with the use of phosphodiesterase inhibitors in at-risk
opulations (11,12). Thus, although the number of ob-
erved events was small, it was reassuring to note no increase
n cardiac ischemic events or heart failure associated with
M-702 (Table 5). Four cases of syncope were associated
ith 8-mg NM-702 use, 2 of which were characterized as
erious adverse events (Table 6). Of note, none of these
atients reported using nitrates while taking NM-702. The
mall number of cases precludes definitive interpretation
ith respect to either the mechanism of these events or their
asual relationship with NM-702 use. Nonetheless, given
he theoretical potential for orthostatic hypotension or
achyarrhythmias associated with phosphodiesterase inhibi-
ion, attention should be paid to any similar events in future
M-702 trials. Furthermore, although no effect of NM-
02 on QT interval was identified in phase I trials, no
ormal assessment of the drug’s effect on this important
arameter was made in the current study.
NM-702 inhibits platelet aggregation, and thus bleeding
vents might be a risk with the drug’s use. Background
herapy with aspirin or clopidogrel was widely used in the
tudy cohort, and bleeding events were rare. Two serious
dverse events due to bleeding or coagulopathy occurred in
atients taking NM-702. Both of these patients were taking
arfarin, raising the possibility of pharmacokinetic and
harmacodynamic drug interactions. Formal assessment of
M-702’s interactions with warfarin and antiplatelet drugs
ill be required to address these potential interactions.
In conclusion, 8 mg NM-702 twice daily was associated
ith significant functional improvements in patients with
AD manifesting as claudication. NM-702 was reasonably
ell tolerated, and no unanticipated safety concerns were
stablished. NM-702 has the potential to provide an addi-
ional therapeutic option for patients with claudication if
uture studies confirm its safety and efficacy.
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